274263-65-9: Levosimendan Cyanoacetamide Hydrazone Impurity

It is an impurity present in Levosimendan, Levosimendan increases myofilament calcium sensitivity by binding to cardiac troponin C in a calcium-dependent manner. by stabilizing the calcium-induced conformational change of troponin C by changing actin-myosin. cross-bridge kinetics apparently without increasing the cycling rate of the cross bridges increasing the effects of calcium on cardiac myofilaments during systole, also have a selective phosphodiesterase (PDE)-III inhibitory action. levosimendan acts preferentially as a Ca2+ sensitizer at lower concentrations whereas at higher concentrations its action as a PDE-III inhibitor becomes more prominent in experimental animals and humans.

Additional information on CAS 274263-65-9

Catalogue No.

VE006146

CAS No.

274263-65-9

Molecular Formula

C14H14N6O2

Molecular Weight

298.3

Parent drug

Levosimendan

IUPAC Name

2-Cyano-2-[[4-[(4R)-1, 4, 5, 6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl]phenyl]hydrazono]-acetamide

Synonyms

N/A

References

Conti, N., Gatti, M., Raschi, E., Diemberger, I., & Potena, L. (2021). Evidence and Current Use of Levosimendan in the Treatment of Heart Failure: Filling the Gap. Drug Design, Development and Therapy, Volume 15, 3391–3409. https://doi.org/10.2147/dddt.s295214

Status

In-stock